BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline
2025-10-14 16:24:38 ET
The last time I spoke about BeOne Medicines AG ( ONC ), it was in a Seeking Alpha article entitled "BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion." With respect to this article, I noted that it had received a positive opinion from the CHMP, a European body, for its development of its PD-1 inhibitor TEVIMBRA so that it can expand its label to include the targeting of patients with untreated [1st-line] gastro/gastroesophageal junction cancer and 1st-line esophageal squamous cell carcinoma [ESCC patients]....
Read the full article on Seeking Alpha
For further details see:
BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology PipelineNASDAQ: BEIGF
BEIGF Trading
0.0% G/L:
$23.75 Last:
100 Volume:
$23.75 Open:



